深圳市亚辉龙生物科技股份有限公司 2025年度业绩预告

Core Viewpoint - The company, Yahui Long Biotechnology Co., Ltd., anticipates a significant decline in net profit for the fiscal year 2025, primarily due to reduced domestic market demand and adverse industry policies [2][5]. Financial Performance Forecast - The company expects a net profit attributable to shareholders of the parent company to be between 20 million and 30 million yuan for 2025, representing a decrease of 27.15 million to 28.15 million yuan, or a year-on-year decline of 90.05% to 93.37% [2]. - The forecasted net profit, excluding non-recurring gains and losses, is projected to be between 65 million and 85 million yuan, reflecting a decrease of 20.23 million to 22.23 million yuan, or a year-on-year decline of 70.42% to 77.38% [2]. Previous Year Performance - In 2024, the net profit attributable to shareholders of the parent company was 301.53 million yuan, and the net profit after excluding non-recurring gains and losses was 287.33 million yuan [4]. Reasons for Performance Change - The decline in performance is attributed to reduced market demand due to industry policy impacts, leading to lower operating revenue and gross margin compared to the previous year [5]. - The company incurred losses from fair value changes in its trading financial assets, specifically stocks of Yunkang Group [5]. - The company plans to recognize impairment losses on various assets based on prudence principles as per accounting standards [5]. - Despite challenges in domestic marketing due to medical industry policies, the company continues to focus on innovation and expanding its product offerings in key clinical areas [5]. Product Development and Achievements - By the end of 2025, the company has expanded its domestic chemiluminescence product menu to 180 items, providing comprehensive solutions for clinical testing [6]. - The company has received a national patent for a specific testing kit and has achieved significant milestones in the development of innovative biomarkers [6]. - The company actively participates in the drafting of national standards for medical automation systems, contributing to the standardization and development of laboratory automation in China [6].